Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut - MarketScreener

Retrieved on: 2024-06-29 04:58:26

Tags for this article:

Initial public offering

SoftBank Group

Leerink Partners

Corporate finance

Click the tags to see associated articles and topics

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut - MarketScreener. View article details on hiswai:

Summary

The article discusses biopharma firm Alumis' IPO performance, where shares fell below the IPO price. It also mentions other companies' IPO struggles and the broader IPO market's challenges. Leerink Partners and SoftBank Group are involved in related corporate finance activities.

Article found on: www.marketscreener.com

View Original Article